New weight loss pill HRS9531 enters final testing phase

NCT ID NCT07670884

Recruiting now Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This phase 3 trial tests whether HRS9531 tablets can help overweight or obese adults lose weight over 52 weeks. About 425 participants will receive either the drug or a placebo. The study measures weight change and the proportion of people losing at least 5% of their body weight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS9531 tablet
What this could lead to: If successful, this could provide a new medication option for significant weight loss in people who are overweight or obese.
What could go wrong: This is a phase 3 trial, but results are not yet available. The drug may cause side effects or not work better than placebo. Long-term safety and effectiveness are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MANAGEMENT OF BODY WEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MANAGEMENT OF BODY WEIGHT

Contacts and locations

Locations

Henan Provincial People's Hospital
RECRUITING

Zhengzhou, Henan, 450003, China
Nanjing Drum Tower hospital
RECRUITING

Nanjing, Jiangsu, 210008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.